Pharmaceutical Preparations · X0 · CIK 1802768
Largest buyer of biopharmaceutical royalties, funding innovation by acquiring rights to future sales of therapies
Comparable business profile · signals at a glance
In the 90 days to Mar 23, 2026: 2 sold $25.3M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 23, 2026 | Coyne Terrance P.EVP & CFO | Sell | 32,916 | $45.53 | $1.5M |
| Mar 23, 2026 | Coyne Terrance P.EVP & CFO | Sell | 1,875 | $45.53 | $85K |
| Mar 2, 2026 | Coyne Terrance P.EVP & CFO | Sell | 22,487 | $46.67 | $1.0M |
| Mar 2, 2026 | Coyne Terrance P.EVP & CFO | Sell | 10,429 | $47.01 | $490K |
| Mar 2, 2026 | Coyne Terrance P.EVP & CFO | Sell | 1,292 | $46.67 | $60K |
| Mar 2, 2026 | Coyne Terrance P.EVP & CFO | Sell | 583 | $47.01 | $27K |
| Feb 23, 2026 | Coyne Terrance P.EVP & CFO | Sell | 32,916 | $45.32 | $1.5M |
| Feb 23, 2026 | Coyne Terrance P.EVP & CFO | Sell | 1,875 | $45.32 | $85K |
| Feb 4, 2026 | Coyne Terrance P.EVP & CFO | Sell | 19,076 | $43.29 | $826K |
| Feb 4, 2026 | Coyne Terrance P.EVP & CFO | Sell | 1,087 | $43.29 | $47K |
| Feb 3, 2026 | Coyne Terrance P.EVP & CFO | Sell | 108,759 | $42.84 | $4.7M |
| Feb 3, 2026 | Coyne Terrance P.EVP & CFO | Sell | 6,195 | $42.84 | $265K |
| Feb 2, 2026 | Coyne Terrance P.EVP & CFO | Sell | 102,581 | $42.08 | $4.3M |
| Feb 2, 2026 | Coyne Terrance P.EVP & CFO | Sell | 5,843 | $42.08 | $246K |
| Jan 30, 2026 | Urist MarshallEVP, Research & Investments | Sell | 20,000 | $41.09 | $822K |
| Jan 23, 2026 | Urist MarshallEVP, Research & Investments | Sell | 20,000 | $40.26 | $805K |
| Jan 20, 2026 | Coyne Terrance P.EVP & CFO | Sell | 65,832 | $39.35 | $2.6M |
| Jan 20, 2026 | Coyne Terrance P.EVP & CFO | Sell | 3,750 | $39.35 | $148K |
| Jan 16, 2026 | Urist MarshallEVP, Research & Investments | Sell | 20,000 | $39.52 | $790K |
| Jan 9, 2026 | Urist MarshallEVP, Research & Investments | Sell | 20,000 | $40.78 | $816K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Coverage (30d): 1 reputable article.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗